English
Home > Products > 7488-56-4

China 7488-56-4 Factory

We purpose to understand high quality disfigurement with the output and supply the top service to domestic and overseas buyers wholeheartedly for 7488-56-4,CAS NO 7488-56-4,Selenium API,Selenium, Seeing believes! We sincerely welcome the new prospects abroad to set up company interactions and also expect to consolidate the interactions with all the long-established clients.
7488-56-4, All the employees in factory, store, and office are struggling for one common goal to provide better quality and service. Real business is to get win-win situation. We would like to provide more support for customers. Welcome all nice buyers to communicate details of our products and solutions with us!

Related Products

Hot Products

  • Fmoc-Asn(Trt)-OH

    Fmoc-Asn(Trt)-OH

    Product Name:Fmoc-Asn(Trt)-OH
    Molecular Formula:C38H32N2O5
    Molecular Weight:596.67
    CAS Registry Number:132388-59-1
  • PantoprazoleSodiumSesquihydrate

    PantoprazoleSodiumSesquihydrate

    Product Name:PantoprazoleSodiumSesquihydrate
    Molecular Formula:C16H18F2N3NaO5S
    Molecular Weight;425.38
    CAS Registry Number;164579-32-2
  • CERIUM(III) CHLORIDE HEPTAHYDRATE

    CERIUM(III) CHLORIDE HEPTAHYDRATE

    Product Name:CERIUM(III) CHLORIDE HEPTAHYDRATE
    Molecular Formula:CeCl3H14O7
    Molecular Weight:372.58
    CAS Registry Number:18618-55-8
  • Methyl 2-bromomethyl-3-nitrobenzoate

    Methyl 2-bromomethyl-3-nitrobenzoate

    Product Name:Methyl 2-bromomethyl-3-nitrobenzoate
    Molecular Formula:C9H8BrNO4
    Molecular Weight:274.07
    CAS Registry Number:98475-07-1
  • N-Methoxy-N-methylacetamide

    N-Methoxy-N-methylacetamide

    Product Name:N-Methoxy-N-methylacetamide
    Molecular Formula:C4H9NO2
    Molecular Weight:103.12
    CAS Registry Number:78191-00-1
  • Methyl 4-amino-5-ethylsulfonyl-2-methoxybenzoate

    Methyl 4-amino-5-ethylsulfonyl-2-methoxybenzoate

    Product Name:Methyl 4-amino-5-ethylsulfonyl-2-methoxybenzoate
    Molecular Formula:C11H15NO5S
    Molecular Weight:273.31
    CAS Registry Number:80036-89-1
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 7488-56-4

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept